profit from every $100 of sales.
$0$100
iHuman
$1.07+4.90% today
-60.5% in 1 year
1-year low $1.021-year high $2.96
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $3.82 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What iHuman sold, what it kept, and what it did with the cash.
Sales went from CN¥986 million in 2022 to CN¥807 million in 2025, with CN¥95.4 million of profit last year.
SalesProfit
iHuman handed back more cash to shareholders than it generated last year.
Buybacks CN¥17MCN¥39M
Free cash flow 2025CN¥46M
Bought back its own sharesCN¥17M
Paid as dividendsCN¥39M
Cash vs. debtCN¥1.2B vs. CN¥11M
iHuman vs. similar companies
iHuman grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| iHuman | 3.8× · Cheap | ||
 New Oriental Education & Technology Group | 22.0× · Fair price | ||
 TAL Education Group | 66.0× · Very expensive | ||
 Graham | 17.4× · Fair price | ||
 Laureate Education | 17.2× · Fair price |
AI analysis
An AI analyst reads iHuman's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 986 | 1,018 | 922 | 807 | |
| 691 | 721 | 640 | 548 | |
| 112 | 160 | 72 | 67 | |
| 122 | 172 | 86 | 75 | |
| 110 | 181 | 99 | 95 | |
| 2.03 | 3.30 | 1.82 | – | |
| 70.1% | 70.8% | 69.4% | 67.9% | |
| 11.3% | 15.7% | 7.8% | 8.3% | |
| 11.1% | 17.8% | 10.7% | 11.8% |
Balance sheet
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,333 | 1,450 | 1,420 | 1,368 |
| Cash | 1,050 | 1,214 | 1,123 | 1,151 |
| Total debt | 9 | 4 | 15 | 11 |
| Total liabilities | 564 | 493 | 459 | 373 |
| 769 | 958 | 961 | 995 | |
| 54 | 55 | 54 | – | |
| 11.3% | 13.1% | 5.8% | 5.2% | |
| 14.3% | 18.9% | 10.3% | 9.6% |
Cash flow
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 188 | 172 | 59 | 51 | |
| 7 | 7 | 7 | 5 | |
| 182 | 166 | 51 | 46 | |
| Dividends paid | 0 | 0 | 35 | 39 |
| 7 | 10 | 10 | 17 | |
| 13 | 9 | 3 | 1 |
Valuation
- 3.8×
- –
- –
- 0.4×
- 0.5×
- 7.9×
- –
- 12.7%
- 26.2%
- 11.0%
Profitability
- 67.9%
- 8.3%
- 11.8%
- 8.3%
- 5.4%
- 9.1%
- 9.8%
- 6.9%
- 6.6%
- 25.8%
Growth
- −6.4%
- –
- −11.6%
- –
- −0.3%
Financial health
- -15.3×
- 0.01
- 0.8%
- –
- 3.57
- 3.51
- 0.59
How it ranks in Consumer Staples
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 19%of 670
Bottom 41%of 674
Top 1%of 624
Bottom 4%of 673
Top 14%of 668
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 16, 2026 | 0.04 | – | – |
| Dec 29, 2025 | 0.06 | – | – |
| Sep 18, 2025 | 0.08 | – | – |
| Jun 26, 2025 | 0.07 | – | – |
| Mar 25, 2025 | 0.07 | – | – |
| Dec 26, 2024 | 0.07 | – | – |
| Sep 27, 2024 | 0.06 | – | – |
| Jun 28, 2024 | 0.06 | – | – |
11.0%of the share price, paid each year
On $1,000 invested$110a year at today's yield, before tax
–per share
Raised–not every year
Paid per share, each year
$0.10 in 2024 → $0.10 in 2025
How safe it looks
41.0% of its profit
Room to growStretchedMore than it earns: 84.2%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
59No pass
Benjamin Graham
100Pass
Philip Fisher
59No pass
Peter Lynch
50No pass
Joel Greenblatt
36No pass
Charlie Munger
52No pass
Terry Smith
36No pass
Questions about iHuman
Is iHuman a good stock to buy?
A solid business, and the price looks low. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the iHuman AI analysis
What does iHuman do?
iHuman Inc., together with its subsidiaries, provides an integrated suite of tech-powered intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. It is in Education & Training Services.
Does iHuman pay a dividend?
Yes. At today's price the dividend is 11.0% a year, about 41% of its yearly profit. In 2025 it paid out $39.1 million in dividends.
Is iHuman stock halal?
No. iHuman does not pass our halal screen: its cash and confirmed interest-bearing investments are 316% of its market value, at or above the 33% limit. How we check
How has iHuman stock done over the past year?
Down 60.5% over the past twelve months, to $1.07. It traded between $1.02 and $2.96 and is 63.9% below its high.
Who are iHuman's competitors?
The largest listed companies in the same industry are New Oriental Education & Technology Group, TAL Education Group, Graham and Laureate Education. The peers table on this page compares their profit, growth and price with iHuman's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.